Conditions: Age-related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion
Keywords: macular degeneration diabetic macular edema vein occlusion vascular endothelial growth factor
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 56
Healthy volunteers: no

Brief summary:
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor. In the present prospective study, the investigators evaluated serum drug levels and plasma free vascular endothelial growth factor (VEGF) levels in patients with neovascular age-related macular degeneration following intravitreal injections of ranibizumab, bevacizumab and aflibercept.

Detailed description:

Arms:
arm 1: Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy. arm 2: Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy. arm 3: Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.

Interventions: intervention 1: Blood Sample Collection intervention 2: Aflibercept intervention 3: Bevacizumab intervention 4: Ranibizumab
Intervention descriptions: intervention 1: Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF. intervention 2: an intravitreal injection of Aflibercept administered three times on a monthly basis. intervention 3: an intravitreal injection of Bevacizumab administered three times on a monthly basis. intervention 4: an intravitreal injection of Ranibizumab administered three times on a monthly basis.

Protocol document: